4.6 Article

The Open Reading Frame 3a Protein of Severe Acute Respiratory Syndrome-Associated Coronavirus Promotes Membrane Rearrangement and Cell Death

期刊

JOURNAL OF VIROLOGY
卷 84, 期 2, 页码 1097-1109

出版社

AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.01662-09

关键词

-

类别

资金

  1. National Institutes of Health-University of Oxford
  2. National Institutes of Allergy and Infectious Diseases
  3. National Institutes of Health
  4. NIH AID [AI059136]
  5. MRC [G0801508, G0400720, MC_U137881015] Funding Source: UKRI
  6. Medical Research Council [MC_U137881015, G0801508, G0400720] Funding Source: researchfish
  7. National Institute for Health Research [NF-SI-0507-10303] Funding Source: researchfish

向作者/读者索取更多资源

The genome of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) contains eight open reading frames (ORFs) that encode novel proteins. These accessory proteins are dispensable for in vitro and in vivo replication and thus may be important for other aspects of virus-host interactions. We investigated the functions of the largest of the accessory proteins, the ORF 3a protein, using a 3a-deficient strain of SARS-CoV. Cell death of Vero cells after infection with SARS-CoV was reduced upon deletion of ORF 3a. Electron microscopy of infected cells revealed a role for ORF 3a in SARS-CoV induced vesicle formation, a prominent feature of cells from SARS patients. In addition, we report that ORF 3a is both necessary and sufficient for SARS-CoV-induced Golgi fragmentation and that the 3a protein accumulates and localizes to vesicles containing markers for late endosomes. Finally, overexpression of ADP-ribosylation factor 1 (Arf1), a small GTPase essential for the maintenance of the Golgi apparatus, restored Golgi morphology during infection. These results establish an important role for ORF 3a in SARS-CoV-induced cell death, Golgi fragmentation, and the accumulation of intracellular vesicles.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Microbiology

The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants

Chang Liu, Daming Zhou, Rungtiwa Nutalai, Helen M. E. Duyvesteyn, Aekkachai Tuekprakhon, Helen M. Ginn, Wanwisa Dejnirattisai, Piyada Supasa, Alexander J. Mentzer, Beibei Wang, James Brett Case, Yuguang Zhao, Donal T. Skelly, Rita E. Chen, Sile Ann Johnson, Thomas G. Ritter, Chris Mason, Tariq Malik, Nigel Temperton, Neil G. Paterson, Mark A. Williams, David R. Hall, Daniel K. Clare, Andrew Howe, Philip J. R. Goulder, Elizabeth E. Fry, Michael S. Diamond, Juthathip Mongkolsapaya, Jingshan Ren, David Stuart, Gavin R. Screaton

Summary: This study investigated several variants of SARS-CoV-2 and found that the Beta variant has the largest antigenic difference compared to other variants, such as Delta, and is poorly neutralized by serum from early pandemic and Delta viruses. The study also revealed that certain antibodies can recognize conserved neutralizing epitopes, while others target specific mutated residues in the Beta variant.

CELL HOST & MICROBE (2022)

Letter Medicine, General & Internal

Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum

Wanwisa Dejnirattisai, Robert H. Shaw, Piyada Supasa, Chang Liu, Arabella S. V. Stuart, Andrew J. Pollard, Xinxue Liu, Teresa Lambe, Derrick Crook, Dave I. Stuart, Juthathip Mongkolsapaya, Jonathan S. Nguyen-Van-Tam, Matthew D. Snape, Gavin R. Screaton

LANCET (2022)

Article Medicine, General & Internal

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

Sue Ann Costa Clemens, Lily Weckx, Ralf Clemens, Ana Verena Almeida Mendes, Alessandra Ramos Souza, Mariana B. Silveira, Suzete Nascimento Farias da Guarda, Maristela Miyamoto de Nobrega, Maria Isabel de Moraes Pinto, Isabela G. S. Gonzalez, Natalia Salvador, Marilia Miranda Franco, Renata Navis de Avila Mendonca, Isabelle Silva Queiroz Oliveira, Bruno Solano de Freitas Souza, Mayara Fraga, Parvinder Aley, Sagida Bibi, Liberty Cantrell, Wanwisa Dejnirattisai, Xinxue Liu, Juthathip Mongkolsapaya, Piyada Supasa, Gavin R. Screaton, Teresa Lambe, Merryn Voysey, Andrew J. Pollard

Summary: A study was conducted to evaluate the safety and immunogenicity of a third dose of heterologous or homologous vaccines in Brazilian adults who had previously received two doses of CoronaVac. The results showed that a third dose of heterologous vaccines (recombinant adenoviral vectored vaccine or mRNA vaccine) significantly increased immune responses and could improve protection against infection.

LANCET (2022)

Article Medicine, General & Internal

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial

Arabella S. Stuart, Robert H. Shaw, Xinxue Liu, Melanie Greenland, Parvinder K. Aley, Nick J. Andrews, J. C. Cameron, Sue Charlton, Elizabeth A. Clutterbuck, Andrea M. Collins, Tom Darton, Tanya Dinesh, Christopher J. A. Duncan, Anna England, Saul N. Faust, Daniela M. Ferreira, Adam Finn, Anna L. Goodman, Christopher A. Green, Bassam Hallis, Paul T. Heath, Helen Hill, Bryn M. Horsington, Teresa Lambe, Rajeka Lazarus, Vincenzo Libri, Patrick J. Lillie, Yama F. Mujadidi, Ruth Payne, Emma L. Plested, Samuel Provstgaard-Morys, Maheshi N. Ramasamy, Mary Ramsay, Robert C. Read, Hannah Robinson, Gavin R. Screaton, Nisha Singh, David P. J. Turner, Paul J. Turner, Iason Vichos, Rachel White, Jonathan S. Nguyen-Van-Tam, Matthew D. Snape

Summary: The study investigated the mixed use of different COVID-19 vaccines within the same schedule, showing that in certain conditions, heterologous vaccination can achieve similar immunogenicity to homologous vaccination, facilitating rapid global vaccine deployment.

LANCET (2022)

Article Immunology

An immunodominant NP105-113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease

Yanchun Peng, Suet Ling Felce, Danning Dong, Frank Penkava, Alexander J. Mentzer, Xuan Yao, Guihai Liu, Zixi Yin, Ji-Li Chen, Yongxu Lu, Dannielle Wellington, Peter A. C. Wing, Delaney C. C. Dominey-Foy, Chen Jin, Wenbo Wang, Megat Abd Hamid, Ricardo A. Fernandes, Beibei Wang, Anastasia Fries, Xiaodong Zhuang, Neil Ashley, Timothy Rostron, Craig Waugh, Paul Sopp, Philip Hublitz, Ryan Beveridge, Tiong Kit Tan, Christina Dold, Andrew J. Kwok, Charlotte Rich-Griffin, Wanwisa Dejnirattisa, Chang Liu, Prathiba Kurupati, Isar Nassiri, Robert A. Watson, Orion Tong, Chelsea A. Taylor, Piyush Kumar Sharma, Bo Sun, Fabiola Curion, Santiago Revale, Lucy C. Garner, Kathrin Jansen, Ricardo C. Ferreira, Moustafa Attar, Jeremy W. Fry, Rebecca A. Russell, Hans J. Stauss, William James, Alain Townsend, Ling-Pei Ho, Paul Klenerman, Juthathip Mongkolsapaya, Gavin R. Screaton, Calliope Dendrou, Stephen N. Sansom, Rachael Bashford-Rogers, Benny Chain, Geoffrey L. Smith, Jane A. McKeating, Benjamin P. Fairfax, Paul Bowness, Andrew J. McMichael, Graham Ogg, Julian C. Knight, Tao Dong

Summary: Specific CD8(+) T cell responses targeting NP105-113-B*07:02 are associated with mild COVID-19 disease and high antiviral efficacy, providing potential targets for T cell vaccine design. These T cell responses show long-lasting preservation of antiviral functionality post-infection.

NATURE IMMUNOLOGY (2022)

Editorial Material Medicine, General & Internal

What influenza activity can we anticipate in 2022?

Kanta Subbarao

Summary: We have been fortunate to avoid the co-circulation of influenza and SARS-CoV-2 since 2020, but this situation is likely to change.

MEDICAL JOURNAL OF AUSTRALIA (2022)

Article Virology

Opposing Effects of Prior Infection versus Prior Vaccination on Vaccine Immunogenicity against Influenza A(H3N2) Viruses

Annette Fox, Louise Carolan, Vivian Leung, Hoang Vu Mai Phuong, Arseniy Khvorov, Maria Auladell, Yeu-Yang Tseng, Pham Quang Thai, Ian Barr, Kanta Subbarao, Le Thi Quynh Mai, H. Rogier van Doorn, Sheena G. Sullivan

Summary: Prior vaccination and infection have different effects on the immunogenicity and effectiveness of influenza vaccines. In this study, prior infection enhanced vaccine immunogenicity, while prior vaccination attenuated it. Comparing antibody responses to A(H3N2) viruses, it was found that prior infection increased antibody titers, while prior vaccination decreased them. This study highlights the importance of considering the immunological history when developing new vaccine strains.

VIRUSES-BASEL (2022)

Editorial Material Biotechnology & Applied Microbiology

A new route to vaccines using PROTACs

Brad Gilbertson, Kanta Subbarao

Summary: An influenza vaccine is created by attenuating the live virus through targeted proteolysis.

NATURE BIOTECHNOLOGY (2022)

Article Cell Biology

Elicitation of pneumovirus-specific B cell responses by a prefusion-stabilized respiratory syncytial virus F subunit vaccine

Emily Phung, Lauren A. Chang, Maryam Mukhamedova, Lijuan Yang, Deepika Nair, Scott A. Rush, Kaitlyn M. Morabito, Jason S. McLellan, Ursula J. Buchholz, John R. Mascola, Michelle C. Crank, Grace Chen, Barney S. Graham, Tracy J. Ruckwardt

Summary: RSV pre-F vaccination results in expansion and activation of RSV and HMPV F-specific B cells that contribute to long-term pneumovirus immunity.

SCIENCE TRANSLATIONAL MEDICINE (2022)

Article Immunology

Intranasal immunization with avian paramyxovirus type 3 expressing SARS-CoV-2 spike protein protects hamsters against SARS-CoV-2

Hong-Su Park, Yumiko Matsuoka, Cindy Luongo, Lijuan Yang, Celia Santos, Xueqiao Liu, Laura R. H. Ahlers, Ian N. Moore, Sharmin Afroz, Reed F. Johnson, Bernard A. P. Lafont, David W. Dorward, Elizabeth R. Fischer, Craig Martens, Siba K. Samal, Shirin Munir, Ursula J. Buchholz, Cyril Le Nouen

Summary: This study used avian paramyxovirus type 3 (APMV3) as an intranasal vaccine vector to express the SARS-CoV-2 spike (S) protein. It was found that a single intranasal dose of APMV3/S-6P induced strong antibody responses and provided protection against SARS-CoV-2, demonstrating high immunogenicity and safety.

NPJ VACCINES (2022)

Editorial Material Immunology

Mammalian infections with highly pathogenic avian influenza viruses renew concerns of pandemic potential

Brad Gilbertson, Kanta Subbarao

Summary: There is a widespread and unprecedented spread of highly pathogenic avian influenza A H5N1 viruses in bird species on five continents, with infections also reported in mammals, most likely caused by consuming infected birds. The increase in H5N1 virus infections in different species could lead to the emergence of new viral variants that may adapt to mammals and potentially humans. It is crucial to monitor and assess the presence of mutations in mammalian-origin H5N1 clade 2.3.4.4b viruses that could increase their risk for human pandemics. Although there have been a limited number of human cases so far, the infection of mammals provides opportunities for the virus to acquire mutations that enhance infection, replication, and spread in mammals, which were not observed in the past viruses.

JOURNAL OF EXPERIMENTAL MEDICINE (2023)

Article Biochemistry & Molecular Biology

Predicting the efficacy of variant-modified COVID-19 vaccine boosters

David S. Khoury, Steffen S. Docken, Kanta Subbarao, Stephen J. Kent, Miles P. Davenport, Deborah Cromer

Summary: Booster vaccination is necessary to combat waning immunity and variants of SARS-CoV-2. Data on neutralization titers from multiple sources suggest that using ancestral vaccines can enhance protection against symptomatic and severe disease caused by variant viruses. Variant-modified vaccines may provide additional benefits. This study provides evidence-based guidance for future COVID-19 vaccine regimens.

NATURE MEDICINE (2023)

Article Virology

Role of the viral polymerase during adaptation of influenza A viruses to new hosts

Brad Gilbertson, Melanie Duncan, Kanta Subbarao

Summary: This review discusses the crucial role of viral polymerase in host adaptation of influenza A viruses (IAV), focusing on the interactions between viral polymerase genes and host factors. The known viral mutations and the adaptation of avian IAV to mammalian hosts are also highlighted.

CURRENT OPINION IN VIROLOGY (2023)

Article Microbiology

Comparative Longitudinal Serological Study of Anti-SARS-CoV-2 Antibody Profiles in People with COVID-19

Marilou H. Barrios, Suellen Nicholson, Rowena A. Bull, Marianne Martinello, William Rawlinson, Michael Mina, Jeffrey J. Post, Bernard Hudson, Nicole Gilroy, Andrew R. Lloyd, Pamela Konecny, Francesca Mordant, Mike Catton, Kanta Subbarao, Leon Caly, Julian Druce, Hans J. Netter

Summary: Serological diagnostic assays are crucial for understanding an individual's immunity to SARS-CoV-2, tracking the virus spread, and evaluating population immunity. Through a dot blot assay, researchers compared the antibody profiles of individuals with different severities of COVID-19 and found patient-specific differences in the anti-SARS-CoV-2 antibody responses. These findings highlight the variability in the antibody response and the importance of considering individual differences when assessing protective antibody status.

MICROORGANISMS (2023)

Article Immunology

Off-target effects of bacillus Calmette-Guerin vaccination on immune responses to SARS-CoV-2: implications for protection against severe COVID-19

Nicole L. Messina, Susie Germano, Rebecca McElroy, Rajeev Rudraraju, Rhian Bonnici, Laure F. Pittet, Melanie R. Neeland, Suellen Nicholson, Kanta Subbarao, Nigel Curtis

Summary: BCG vaccination has immunomodulatory effects on SARS-CoV-2 and reduces the secretion of cytokines associated with severe COVID-19. In addition, BCG vaccination promotes specific T cell immune responses and activates eosinophils.

CLINICAL & TRANSLATIONAL IMMUNOLOGY (2022)

暂无数据